Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Melanoma 91Carcinoma, Non-Small-Cell Lung 84Neoplasms 48Carcinoma, Renal Cell 44Neoplasm Metastasis 40Carcinoma, Hepatocellular 36Squamous Cell Carcinoma of Head and Neck 35Colorectal Neoplasms 31Pancreatic Neoplasms 24Lung Neoplasms 20Stomach Neoplasms 19Head and Neck Neoplasms 18Carcinoma, Transitional Cell 17Hodgkin Disease 16Breast Neoplasms 16Small Cell Lung Carcinoma 15Ovarian Neoplasms 14Urinary Bladder Neoplasms 13Recurrence 13Advanced Cancer 13Glioblastoma 12Brain Neoplasms 12Lymphoma 11Kidney Neoplasms 11Glioma 11Prostatic Neoplasms 10Lymphoma, Non-Hodgkin 10Uveal Melanoma 9Triple Negative Breast Neoplasms 9Sarcoma 9

Interventions

Nivolumab 4Ipilimumab 3relatlimab 1daratumumab 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Various Advanced Cancer × Nivolumab × Clear all
NCT03143153 2026-02-17

CheckMate 648

Bristol-Myers Squibb

Phase 3 Completed
970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed
578 enrolled 19 charts

Various Advanced Cancer

NCT02387996 2022-11-01

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Bristol-Myers Squibb

Phase 2 Completed
270 enrolled 14 charts

Various Advanced Cancer

NCT03130959 2022-08-09

CheckMate 908

Bristol-Myers Squibb

Phase 2 Completed
166 enrolled 33 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡